^
Association details:
Biomarker:PTEN mutation
Cancer:Endometrial Cancer
Drug:A66 (PI3K inhibitor) +
AZD6482 (PI3Kβ inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

PI3K pathway dependencies in endometrioid endometrial cancer cell lines

Excerpt:
PTEN-mutant EEC cell lines were resistant to the p110β inhibitors GSK2636771 and AZD6482, and only in combination with the p110α selective inhibitor A66, a decrease in cell viability was observed....hibition of p110β alone may not be sufficient to sensitize PTEN-mutant EEC cells and combination with other targeted agents may be required.
DOI:
10.1158/1078-0432.CCR-12-3815